Use of Pegylated IL-10 to Treat Cancer

Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

1 . A method of inhibiting or reducing growth of a tumor or cancer comprising contacting the tumor with an effective amount of a pegylated interleukin-10 (PEG-IL-10).  
     
     
         2 . The method of  claim 1 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.  
     
     
         3 . The method of  claim 1 , wherein the PEG-IL-10 inhibits growth of the tumor or cancer.  
     
     
         4 . The method of  claim 1 , wherein the PEG-IL-10 reduces the size of the tumor or cancer.  
     
     
         5 . The method of  claim 1 , wherein PEG-IL-10 increases infiltration of CD8+ T cells into the tumor when compared to non-pegylated IL-10.  
     
     
         6 . The method of  claim 1 , wherein PEG-IL-10 increases the expression of at least one inflammatory cytokine.  
     
     
         7 . The method of  claim 6 , wherein the inflammatory cytokine is selected from the group consisting of IFNγ, IL-4, IL-6, IL-10, and RANK-ligand (RANK-L).  
     
     
         8 . The method of  claim 1 , wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent.  
     
     
         9 . The method of  claim 8 , wherein the chemotherapeutic agent is at least one of the chemotherapeutic agents of Table 16.  
     
     
         10 . The method of  claim 1 , wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, and leukemia.  
     
     
         11 . A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of PEG-IL-10.  
     
     
         12 . The method of  claim 11 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.  
     
     
         13 . The method of  claim 11 , wherein the PEG-IL-10 inhibits growth of the cancer or tumor.  
     
     
         14 . The method of  claim 11 , wherein the PEG-IL-10 reduces the size of the tumor or cancer.  
     
     
         15 . The method of  claim 11 , wherein PEG-IL-10 increases infiltration of CD8+ T cells into the tumor when compared to non-pegylated IL-10.  
     
     
         16 . The method of  claim 11 , wherein PEG-IL-10 increases the expression of at least one inflammatory cytokine.  
     
     
         17 . The method of  claim 16 , wherein the inflammatory cytokine is selected from the group consisting of IFNγ, IL-4, IL-6, IL-10, and RANK-L.  
     
     
         18 . The method of  claim 11 , wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent.  
     
     
         19 . The method of  claim 18 , wherein the chemotherapeutic agent is at least one of the chemotherapeutic agents of Table 16.  
     
     
         20 . The method of  claim 11 , wherein PEG-IL-10 reduces metastasis of a cancer or tumor.  
     
     
         21 . The method of  claim 11 , wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, lung cancer, melanoma, glioblastoma, and leukemia.  
     
     
         22 . The method of  claim 11 , wherein the subject is human.  
     
     
         23 . The method of  claim 22 , wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).